Core Viewpoint - Albertsons Companies (NYSE: ACI) presents a compelling investment opportunity for 2026, with strong earnings performance despite bearish price action, indicating potential for stock price recovery and significant gains [2][3]. Valuation and Earnings - Albertsons trades at a low valuation of 8x current-year earnings and 6x the 2030 consensus forecast, which is a discount compared to peers like Kroger, which trades at 12x current earnings [4]. - The company has consistently outperformed earnings expectations, reinforcing a bullish outlook despite current market conditions [2][4]. Dividend Yield - Albertsons offers a reliable dividend of 60 cents, yielding approximately 3.5%, which is higher than competitors like Kroger at 2.25% [5]. - The dividend payout is under 30% of the fiscal year 2025 earnings consensus, indicating sustainability and potential for growth [5]. Market Position and Recovery - Following a failed merger with Kroger, Albertsons is trading at a deep value, with institutional and analyst trends suggesting stock accumulation in 2025 as prices fell [6]. - The combination of a favorable value-and-yield proposition positions Albertsons for a robust rebound in the market [6].

Core Viewpoint - Investors in the Banks - Foreign sector should consider Banco Santander-Chile (BSAC) and Banco De Chile (BCH) for potential investment opportunities, with a focus on which stock offers better value at present [1] Group 1: Zacks Rank and Earnings Outlook - Both BSAC and BCH currently hold a Zacks Rank of 2 (Buy), indicating a positive earnings outlook supported by favorable analyst estimate revisions [3] - The Zacks Rank strategy targets companies with improving earnings estimates, which is a positive sign for investors [2] Group 2: Value Metrics - Value investors utilize various traditional metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] - BSAC has a forward P/E ratio of 12.47, while BCH has a forward P/E of 14.17, suggesting BSAC may be more attractively priced [5] - BSAC's PEG ratio is 0.74, indicating better value relative to its expected earnings growth compared to BCH's PEG ratio of 2.66 [5] Group 3: Price-to-Book Ratio - BSAC has a P/B ratio of 3.25, while BCH's P/B ratio is 3.54, further supporting the argument that BSAC is the more favorable investment option based on valuation metrics [6] Group 4: Overall Value Assessment - Based on the analyzed metrics, BSAC holds a Value grade of B, whereas BCH has a Value grade of D, indicating that BSAC is currently the superior value option [7]

Core Viewpoint - Investors are evaluating BorgWarner (BWA) and Ferrari (RACE) to determine which stock offers better value for investment at the current time [1] Group 1: Zacks Rank and Earnings Outlook - BorgWarner has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Ferrari has a Zacks Rank of 5 (Strong Sell), suggesting a negative earnings outlook [3] - The Zacks Rank emphasizes companies with positive earnings estimate revisions, indicating that BWA is likely experiencing an improvement in its earnings outlook compared to RACE [3] Group 2: Valuation Metrics - BWA has a forward P/E ratio of 9.44, significantly lower than RACE's forward P/E of 33.39, indicating that BWA may be undervalued [5] - The PEG ratio for BWA is 0.93, while RACE has a PEG ratio of 3.90, suggesting that BWA is expected to grow its earnings at a more favorable rate relative to its price [5] - BWA's P/B ratio is 1.65, compared to RACE's P/B of 20.12, further indicating that BWA is more attractively valued [6] Group 3: Overall Value Assessment - Based on various valuation metrics, BWA holds a Value grade of A, while RACE has a Value grade of F, suggesting that BWA is the superior choice for value investors at this time [6]

Core Insights - Investors are evaluating US Foods (USFD) and Celsius Holdings Inc. (CELH) for potential undervalued stock opportunities [1] Group 1: Zacks Rank and Earnings Outlook - US Foods has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Celsius Holdings Inc., which has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank strategy focuses on companies with positive earnings estimate revision trends, which is a key factor for value investors [2] Group 2: Valuation Metrics - USFD has a forward P/E ratio of 16.34, significantly lower than CELH's forward P/E of 34.88, suggesting USFD may be undervalued [5] - The PEG ratio for USFD is 0.81, while CELH's PEG ratio is 0.85, indicating USFD's earnings growth is more favorably priced [5] - USFD's P/B ratio is 3.79, compared to CELH's P/B of 11.01, further highlighting USFD's relative valuation advantage [6] Group 3: Value Grades - Based on various valuation metrics, USFD holds a Value grade of A, while CELH has a Value grade of D, suggesting USFD is the more attractive option for value investors [6]

Core Viewpoint - Symrise AG Unsponsored ADR (SYIEY) is currently more attractive to value investors compared to Givaudan SA (GVDNY) based on various valuation metrics and earnings outlook [3][7]. Valuation Metrics - SYIEY has a forward P/E ratio of 15.84, while GVDNY has a forward P/E of 23.73, indicating that SYIEY is potentially undervalued [5]. - The PEG ratio for SYIEY is 1.06, suggesting a favorable growth outlook compared to GVDNY's PEG ratio of 4.09, which indicates a less attractive growth valuation [5]. - SYIEY's P/B ratio stands at 2.63, significantly lower than GVDNY's P/B of 7.24, further supporting SYIEY's valuation attractiveness [6]. Earnings Outlook - SYIEY is experiencing an improving earnings outlook, which enhances its position in the Zacks Rank model, indicating a positive trend for potential investors [3][7]. - Givaudan SA, on the other hand, has a Zacks Rank of 4 (Sell), suggesting a less favorable earnings outlook compared to SYIEY [3]. Value Grades - SYIEY has been assigned a Value grade of B, while GVDNY has a Value grade of D, reflecting the relative undervaluation of SYIEY [6].

Core Viewpoint - Investors in the Waste Removal Services sector should consider Montrose Environmental (MEG) and Waste Management (WM) for potential undervalued stock opportunities [1] Valuation Metrics - Montrose Environmental has a forward P/E ratio of 17.04, while Waste Management has a forward P/E of 26.06 [5] - MEG's PEG ratio is 0.89, indicating better expected EPS growth compared to WM's PEG ratio of 2.42 [5] - MEG's P/B ratio is 1.94, significantly lower than WM's P/B of 9.14, suggesting MEG is more attractively valued [6] Analyst Outlook - Montrose Environmental holds a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to Waste Management's Zacks Rank of 3 (Hold) [3] - The stronger estimate revision activity for MEG suggests a more positive analyst outlook, making it a more appealing option for value investors [7] Value Grades - MEG has a Value grade of B, while WM has a Value grade of C, reflecting MEG's superior valuation metrics [6]

Core Viewpoint - Investors are evaluating the value opportunities presented by Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA) in the Medical - Biomedical and Genetics sector [1] Group 1: Zacks Rank and Earnings Estimates - HRMY has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to LQDA, which has a Zacks Rank of 3 (Hold) [3] - The stronger earnings estimate revision activity for HRMY suggests an improving analyst outlook, making it a more attractive option for investors [3] Group 2: Valuation Metrics - HRMY has a forward P/E ratio of 10.09, significantly lower than LQDA's forward P/E of 37.43, indicating that HRMY may be undervalued [5] - The PEG ratio for HRMY is 0.39, while LQDA's PEG ratio is 1.03, suggesting that HRMY offers better value relative to its expected earnings growth [5] - HRMY's P/B ratio is 2.59, contrasting sharply with LQDA's P/B of 122.26, further highlighting HRMY's relative undervaluation [6] Group 3: Value Grades - HRMY has been assigned a Value grade of A, while LQDA has a Value grade of D, indicating that HRMY is viewed more favorably by value investors [6] - The combination of Zacks Rank and Style Scores indicates that HRMY is the better investment option compared to LQDA at this time [6]

Core Viewpoint - Hologic (HOLX) is currently more attractive to value investors compared to SONOVA HOLDING (SONVY) based on various valuation metrics and earnings estimate revisions [3][7]. Valuation Metrics - Hologic has a forward P/E ratio of 16.64, while SONVY has a higher forward P/E of 21.56 [5]. - The PEG ratio for Hologic is 2.13, indicating a more favorable valuation in relation to its expected earnings growth compared to SONVY's PEG ratio of 3.27 [5]. - Hologic's P/B ratio stands at 3.3, significantly lower than SONVY's P/B ratio of 5.13, suggesting that Hologic is undervalued relative to its book value [6]. Analyst Outlook - Hologic holds a Zacks Rank of 2 (Buy), indicating a positive analyst outlook, while SONVY has a Zacks Rank of 4 (Sell), reflecting a less favorable outlook [3]. - The stronger estimate revision activity for Hologic further supports its position as a more attractive investment option for value investors [7].

Core Viewpoint - United Therapeutics (UTHR) is currently viewed as a more attractive investment option compared to Madrigal (MDGL) for value investors, based on various valuation metrics and earnings outlook [1][7]. Valuation Metrics - UTHR has a forward P/E ratio of 18.10, significantly lower than MDGL's forward P/E of 184.79, indicating that UTHR may be undervalued relative to its earnings potential [5]. - The PEG ratio for UTHR is 2.61, while MDGL's PEG ratio stands at 3.97, suggesting that UTHR offers better value when considering expected earnings growth [5]. - UTHR's P/B ratio is 3.29, compared to MDGL's P/B of 20.37, further highlighting UTHR's relative undervaluation based on market value versus book value [6]. Earnings Outlook - UTHR is experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, indicating a positive trend in earnings estimates [3][7]. - The Zacks Rank for UTHR is 2 (Buy), while MDGL holds a Zacks Rank of 3 (Hold), reflecting a stronger earnings estimate revision for UTHR [3].

Core Viewpoint - The article compares Genpact (G) and Epam (EPAM) to determine which stock is more attractive to value investors, highlighting the importance of various valuation metrics in this assessment [1]. Group 1: Valuation Metrics - Genpact has a forward P/E ratio of 12.12, while Epam has a forward P/E of 17.40, indicating that Genpact may be undervalued compared to Epam [5]. - Genpact's PEG ratio is 1.26, which is lower than Epam's PEG ratio of 2.13, suggesting that Genpact offers better value when considering expected earnings growth [5]. - Genpact has a P/B ratio of 3.25, slightly lower than Epam's P/B of 3.26, further supporting the argument that Genpact is a more attractive value option [6]. Group 2: Earnings Outlook - Both Genpact and Epam hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks for both companies [3]. - Despite the positive earnings outlook for both companies, value investors will focus on traditional figures and metrics to assess undervaluation [3]. Group 3: Value Grades - Genpact has earned a Value grade of A, while Epam has a Value grade of C, reinforcing the conclusion that Genpact is the superior value option at this time [6].